Clinical Trial Update: A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous Elamipretide for 4 weeks in stable heart failure with preserved ejection fraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Elamipretide (elamipretide)

Snippet

Sponsor: Stealth BioTherapeutics Inc. | Conditions: Chronic Heart Failure | Phase 2 | Status: COMPLETED